<div id="readability-page-1"><p>In a report released today, Mani Foroohar from Leerink Partners reiterated a Buy rating on BridgeBio Pharma, with a price target of <span id="expert-recommendation-target">$86.00</span>.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>Foroohar covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and Ionis Pharmaceuticals. According to TipRanks, Foroohar has an average return of <span>3.0%</span> and a 46.39% success rate on recommended stocks. </p> <p>In addition to Leerink Partners, BridgeBio Pharma also received a Buy from Bernstein’s William Pickering in a report issued on December 11. However, on December 9, TR | OpenAI – 4o reiterated a Hold rating on BridgeBio Pharma (NASDAQ: BBIO).</p></div>

BBIO

<p>Mani Foroohar from Leerink Partners reiterated a Buy rating on BridgeBio Pharma with a price target of $86.00. Foroohar has an average return of 3.0% and a 46.39% success rate on recommended stocks. Additionally, Bernstein's William Pickering also rated BridgeBio Pharma as a Buy, while TR reiterated a Hold rating.</p>

Leerink Partners Remains a Buy on BridgeBio Pharma (BBIO)